Targets › FAK
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout May 2027.
Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. (UniProt, Q05397)
Open in Phaseline: the race on FAK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ascentage Pharma Group | APG-2449 Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor | FAK, ALK, ROS1 | Phase 1 | Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid Cancer | May 2027 |
| Amplia Therapeutics | narmafotinib focal adhesion kinase (FAK) inhibitor | FAK | Phase 1 | Pancreatic Cancer Metastatic | Jul 2029 |
Pancreatic Cancer Metastatic (1) Platinum-resistant Recurrent Ovarian Cancer (1) Advanced Solid Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.